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Abstract
A more detailed understanding of the somatic genetic events that drive gastrointestinal
adenocarcinomas is necessary to improve diagnosis and therapy. Using data from high-density
genomic profiling arrays, we conducted an analysis of somatic copy-number aberrations (SCNAs)
in 486 gastrointestinal adenocarcinomas including 296 esophageal and gastric cancers. Focal
amplifications were substantially more prevalent in gastric/esophageal adenocarcinomas than
colorectal tumors. We identified 64 regions of significant recurrent amplification and deletion,
some shared and others unique to the adenocarcinoma types examined. Amplified genes were
noted in 37% of gastric/esophageal tumors, including in therapeutically targetable kinases such as
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ERBB2, FGFR1, FGFR2, EGFR, and MET, suggesting the potential utility of genomic
amplifications as biomarkers to guide therapy of gastric and esophageal cancers where targeted
therapeutics have been less developed compared to colorectal cancers. Amplified loci implicated
genes with known involvement in carcinogenesis but also pointed to regions harboring potentially
novel cancer genes, including a recurrent deletion found in 15% of esophageal tumors where the
Runt transcription factor subunit RUNX1 was implicated, including by functional experiments in
tissue culture. Together, our results defined genomic features that were common and distinct to
various gut-derived adenocarcinomas, potentially informing novel opportunities for targeted
therapeutic interventions.
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Introduction
Colorectal, gastric, and esophageal adenocarcinomas collectively account for approximately
180,000 cancer diagnoses and 76,500 deaths each year in the United States and
approximately 1.3 million deaths worldwide (1, 2). A better understanding of the somatic
genetics of these diseases is a prerequisite for earlier diagnosis and more effective treatment.
Colorectal cancer (CRC) genomes have been studied extensively (3, 4); the value of this
information is realized by persuasive evidence that KRAS and BRAF mutations in CRC
predict lack of response to cetuximab (5, 6). Gastric cancer (GC) and especially esophageal
adenocarcinoma (EA) has been subjected to fewer large-scale studies (7-9).
Cancers of the esophagus and stomach commonly arise in a background of intestinal
metaplasia, but develop within distinct luminal environments. Nevertheless, they often are
treated with identical chemotherapy, and many clinical trials combine patients with these
two diseases (10, 11). While the process of intestinal metaplasia preceding GC and EA
suggests that these tumors may resemble adenocarcinomas arising from the intestine, they
demonstrate distinct clinical behavior from CRC. It is therefore important to define the
similarities and differences among digestive tract adenocarcinomas at the genomic and
molecular levels. Such a comparison can inform both mechanistic studies and strategies for
biomarker-driven therapy.
Two challenges exist in the somatic genetic analysis of cancer: 1) distinguishing ‘driver’
alterations that contribute to tumor development, maintenance, or proliferation from random
‘passenger’ alterations that do not contribute to the neoplastic process, and 2) identifying the
specific genes that mediate tumor progression. Both challenges must be confronted in
analysis of somatic copy-number alterations (SCNAs) as tumors often harbor many such
alterations, each of which often encompasses up to thousands of genes. The study of SCNAs
has been greatly enhanced by high-density genomic arrays allowing resolution of individual
SCNA boundaries and the ability to study large numbers of tumors. Statistical analysis of
SCNAs across many samples can identify regions altered more frequently than expected by
chance and also pinpoint the most likely culprit genes in these regions. Pooling data from
different but related cancer types can increase both statistical power and the ability to
resolve specific gene targets of SCNAs. Given the related origins and documented shared
copy-number characteristics of gut-derived adenocarcinomas (12), we hypothesized that
evaluating genomic events across these tumors will increase our power to identify common
genes active in gut adenocarcinomas and also help uncover differences. Here, we report the
largest analysis of SCNAs across gut adenocarcinoma genomes and systematically compare
significantly recurrent structural genetic alterations in tumors from distinct regions of the
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gut. We find multiple known and novel recurrent alterations, including region-specific and
shared events.
Materials and Methods
All samples were fresh frozen primary resections from patients not treated with prior
chemotherapy or radiation. All cases had diagnoses confirmed by pathologic review and
only cases with estimated carcinoma content >70% were selected (Supplementary Table 1).
The sample set was not enriched for other features. Tumors annotated as having originated
from the gastric-esophageal junction were assigned to the EA collection. DNA was extracted
(Supplemental Table 1), quantified with Picogreen dye and hybridized to (214 samples)
GeneChip Human Mapping StyI 250K arrays (Affymetrix, Santa Clara, CA) or (271
samples) Genome-Wide Human SNP Array 6.0 (SNP6.0) (Affymetrix) genomic profiling
arrays, according to the manufacturer’s instructions. Data from each of the two array
platforms were independently normalized and segmented using all data present upon each of
the two platforms (12, 13). Regions of known germline copy-number polymorphisms were
then removed as previously described (14). Human genome build hg18 was used, and raw
data files have been deposited at the Gene Expression Omnibus (GSE36460).
Significantly recurrent SCNAs were identified using GISTIC 2.0. (15) All data from each
array were used to generate SCNA profiles for each tumor. To enable probe bound GISTIC
analyses across data from two array platforms, the segmented data from each sample was
remapped to the 196,800 probes shared by the two platforms. In some cases this remapping
modified the position of the probe bounding the transition between two copy-number
segments. In these cases, the boundaries were remapped to the nearest probes in the joint set.
To remove potentially spurious SCNAs, segments defined by fewer than nine shared probes
were removed (16). Additional details are described in Supplemental Methods.
Results
A comprehensive copy-number dataset from digestive tract adenocarcinomas
We analyzed a cohort of 363 new and 123 publically available genome array profiles from
primary untreated gut adenocarcinomas including EA (186), GC (110), and CRC (190)
(Table S1). We determined genome-wide copy-number profiles using either 250K StyI
(238,000 probes) or SNP6.0 genome arrays (1.8 million probes) (Table S1). Copy-number
alterations were identified using the full complement of data from each array type. To enable
the analysis across platforms, the segmented copy-number data from each sample were
remapped to the 196,800 probes common to both arrays. We found no evidence of bias
introduced by pooling samples from the two platforms (Supplemental Note 1).
Chromosomal instability increases from lower to upper gut adenocarcinomas
Across this set of adenocarcinoma SCNA profiles, visual inspection of the segmented data
showed alterations in nearly every part of the genome, and variations in the amount of
genomic disruption between different cancers and cancer types (Fig. 1A). To compare levels
of genomic disruption, we separately evaluated the frequencies of arm-level (comprising
half or more of a chromosome arm) and focal SCNAs in each cancer type. Focal alterations
were noted to occur throughout the chromosomes, but showed some predilection for the
regions closer to the centromeres and telomeres of each chromosome. (Supplemental Figure
1)
The median number of arm-level gains varied little between types (Fig. 1B), but was
significantly increased in focal amplifications in EA and GC compared to CRC (Fig. 1C).
Some tumors, particularly among CRC and GC types, demonstrated little apparent genomic
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disruption, potentially attributable to microsatellite instability or stromal contamination
(Supplemental Note 2). The enhanced rate of focal amplification in EA and GC compared to
CRC remained valid when these genomically quiet tumors were removed from analysis (Fig.
S2). Upper gut adenocarcinomas exhibited an even greater excess of higher-level, multi-
copy focal amplifications (Fig. 1D), which remained after we accounted for possible
contaminating non-cancer DNA through use of sample-specific thresholds for defining these
events (Fig. S3). The higher rates of focal genomic amplifications in EA and GC relative to
CRC suggest that underlying mechanisms of genomic instability may differ between upper
and lower gastrointestinal adenocarcinomas and that genomic amplification may be a more
common means of oncogene activation in GC/EA.
The difference in rates of focal amplifications between upper and lower gastrointestinal
adenocarcinomas did not hold for deletions. Fewer arm-level deletions were seen in GC than
other gut adenocarcinomas (Fig. 1B). There was a modest increase in focal deletions in EA
compared to GC and CRC (Fig. 1B), a trend that persisted when cases without arm-level
SCNAs were excluded (Fig. S2). EA and CRC exhibit similar rates of multi-copy deletions
that may represent homozygous deletions, rates that are significantly higher than in GC (Fig.
1D). This pattern persisted after exclusion of ‘quiet’ samples and used sample-specific
thresholds to identify the multi-copy deletions (Fig. S3). The discordant bias towards focal
amplifications but not deletions in upper gastrointestinal cancers suggests that the
mechanisms and selective pressures leading to amplification may differ from deletion.
Recurrent amplifications and deletions across the pooled dataset
Arm-level events—We next performed a GISTIC 2.0 analysis to define significantly
recurrent SCNAs, starting with arm-level SCNAs. Arm-level amplifications of
chromosomes 7p, 8q, 20p, and 20q recurred significantly across all three cancer types (Fig.
S4A). Events restricted to specific subtypes included 1q gains in GC and 13q gains in CRC
and GC. These significant arm-level gains have been observed previously (17-23). Arm-
level deletions were more variable across tumor types. In GC, deletions of 4p and 4q alone
were significant reflecting a lower degree of arm-level losses detected earlier in GC (Fig.
S4B), but these and other deletions (8p, 18p, 18q) were also detected in EA and CRC. Loss
of arms 8p, 14q, and 15q were of higher significance in CRC, whereas loss of 5q, 9p, and
21q were particularly significant among EAs. Loss of 17p (containing TP53) was significant
in EA and CRC, but not GC. Unique significant losses of 9p and 21q in EA are notable
because these arms respectively contain the known and putative tumor suppressors
CDKN2A and RUNX1, both targets of focal deletion in EA (discussed below).
These results are in accordance with previously published data. We compared the frequency
of alteration for each cytoband in each cancer type to frequencies determined across 998
CRC, 741 GC, and 71 EA in the Progenetix database curated from cCGH and aCGH data
(24, 25). The cytoband-level data are similar for all cancer types, with the exception of
lower frequencies of 17q gain in our GC and EA samples (Fig. S5). Notably, the low
frequency of deletions in GC data compiled by Progenetix mirrored our data suggesting that
result is not unique to the samples in our collection.
Focal alterations—We next evaluated focal SCNAs across all 486 tumors and identified
33 regions subject to significant (q<0.01) focal amplification (Fig. 2 and Table 1). Thirteen
of these regions contain known oncogenes, including four genes involved in cell cycle
regulation (CCNE1, CCND1, CDK6, MYC) and seven members of tyrosine kinase/MAPK
signaling pathways (EGFR, KRAS, MET, ERBB2, FGFR1, FGFR2, and IGF1R). Twenty
significant peaks contained no established oncogenes, suggesting potential presence of novel
Dulak et al. Page 4
Cancer Res. Author manuscript; available in PMC 2013 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
genes or non-coding transcripts that promote intestinal metaplasia and/or gastrointestinal
carcinogenesis.
The 18q11.2 amplification peak is the second most significant peak after KRAS and
contains only the endodermal transcription factor GATA6. Coupled with functional data
suggesting a role for GATA6 in esophageal carcinogenesis (26, 27), these results implicate
GATA6 as an important contributor to gastrointestinal neoplasia. The sixth most significant
peak in the composite dataset, located at 8p23.1, contains 4 genes, including the related
transcription factor GATA4, a candidate target noted previously (28).
We also identified 30 regions of significant focal deletion (Fig. 2 and Table 2). Eight of
these regions include genes such as FHIT and WWOX, with exons spread over large
genomic loci (in excess of 1 Mb). Prior studies suggest that such regions often lie in “fragile
sites” or areas of low gene density where deletion may be tolerated, and may not harbor
functional tumor suppressors (12, 29). An additional eight regions contain the known tumor
suppressors CDKN2A, SMAD4, PTEN, APC, RUNX1, ARID1A, and ATM and the
putative tumor suppressor PARD3B (30). Fourteen regions did not contain known tumor
suppressors or large-footprint genes, but could contain novel factors whose loss contributes
to intestinal metaplasia or cancer. Our analysis would not have detected regions of loss of
heterozygosity that did not lead to copy-number loss.
The combined analysis across three tumor types enabled identification of less common
SCNAs. Five amplification peaks were significant in the composite set but not in any
individual cancer type. One of these, 13q22.1, contains only two genes, including the
proliferative transcription factor KLF5. The combined dataset also enabled more precise
identification of the likely targets of focal SCNAs. For example, the 1p36.11 deletion
narrowed from 89 genes in the EA set to only 11 genes in the combined dataset, including
the chromatin-modifying enzyme ARID1A, a recently identified target of frequent mutation
in clear cell ovarian and gastric adenocarcinomas (31, 32). However, combining data across
platforms also entailed some loss of resolution for the SNP6 data. We therefore performed a
separate analysis of the SNP6 data, which yielded similar results to the composite analysis,
though with fewer peaks (Supplemental Note 3 and Table S6).
To identify relationships between genes targeted by focal alterations, we evaluated the co-
occurrence or exclusivity of focal alterations at all GISTIC peak regions. After correcting
for multiple hypothesis testing and tissue type, the only significant (Bonferroni-corrected p-
value ≥0.05) findings were correlations of amplifications of CCNE1 with each of two peaks
with unknown targets: a deletion peak at 6p25.3 and amplification of 1q42.3. These findings
may suggest cooperativity between these novel events and amplification of CCNE1, or
reflect subsets of tumors that for other reasons tend to share alterations in these regions.
Comparison of focal alterations across gut adenocarcinoma and other cancer types
Comparison of focal amplifications—We analyzed focal alterations in each tumor
type separately and identified five, 14 and 25 amplification peaks in CRC, GC, and EA,
respectively (Figs. 3A and S6 and Table S2). Highlighting the similarities and differences
among digestive tract cancers, only three amplifications were significant in all tumor types:
8q24.21 (containing MYC), 17q12 (containing ERBB2), and 18q11.2 (containing GATA6).
Among these peaks, ERBB2 is amplified more commonly in esophageal (17%) and gastric
(13%) than in colorectal (6%) tumors (Fig. S7).
Two amplification peaks were restricted to colorectal cancers. One amplicon contains the
RTK, FGFR1, not previously reported in this disease, but noted to be overexpressed (33).
The other unique peak is adjacent to the CRC oncogene CDK8 at 13q12.2 (34). Esophageal
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and gastric adenocarcinomas shared seven amplicons, containing VEGFA, EGFR, GATA4,
CCND1, MDM2, CCNE1, and KRAS. The most significantly amplified gene across our
dataset, KRAS, showed a strong foregut preference. Only 5% of CRCs carried focal KRAS
amplification, compared to 21% of upper GI cancers. Conversely, CRCs have substantially
higher rates of KRAS mutation (Fig. S8) demonstrating how upper and lower
gastrointestinal cancers show distinct ways of altering the same oncogene (35).
An additional 14 regions of amplification were specific to EA. Six of these peaks contained
genes known to contribute to cancer (CDK6, MCL1, PRKCI, MYB, MET, and FGFR2),
while the others contain no previously described oncogenes. To evaluate how the large
sample size enabled identification of relevant targets, we compared our analysis to the
SCNA analyses of the largest previously published EA datasets, comprising 42 and 56
tumors (8, 36). Amplifications at CCNE1, MET, FGFR2 and MYB were not identified in
previous datasets, but these genes have been noted to be overexpressed in EA (37-40). Many
peaks that lack known oncogenes were also not noted in earlier reports. Although MET and
CCNE1 amplifications had been detected previously by focused gene inquiry, MYB and
FGFR2 amplifications were not noted in prior data. Our sample numbers also afforded
greater resolution to identify targets of previously identified SCNAs. For example, an
amplicon at 6p21.1 was reported in studies of 42 and 56 EAs to contain between 50 and 70
genes (8, 36). We narrowed this region to only 2 genes, including the vascular endothelial
growth factor, VEGFA, the target of the therapeutic antibody bevacizumab. A prior study of
EA also identified a 94-gene region of amplification on 3q and attributed this event to
PIK3CA (36). Our analysis narrows this peak to a region containing PRKCI, >5 Mb away
from PIK3CA.
The presence of FGFR2 amplifications in EA suggests a potential new therapeutic target for
these tumors, similar to in GC (9). We confirmed the presence of FGFR2 amplification in
individual EA cases through quantitative RT-PCR (Fig. S9). These results indicate FGFR2
amplification may serve as a biomarker for the use of FGFR2-directed therapy in EA in
addition to GC.
Four amplification peaks were restricted to gastric adenocarcinoma. Among these, only
3q27.1, containing the RTK gene, EPHB3, has been suggested to play a role in cancer
progression (41). Compared to prior studies, we not only confirmed recurrent focal
amplifications involving GATA4 and GATA6, but also identified novel peaks on 6p21.1
(VEGFA), 3q27.1 (EPHB3), 1p36.22, 12q15, and 1q42.3 (9).
The most significant focally amplified tyrosine kinases, ERBB2, EGFR, MET, FGFR1, and
FGFR2, are known oncogenes and targets of therapeutic agents in current use or
development. We detected amplifications involving one or more RTKs in 42% of EA, 28%
of GC, and 14% of CRC samples (Fig. 4). Only 10% of tumors had concurrent
amplifications of RTKs and KRAS.
Finally, we compared amplifications in GI adenocarcinomas to those found in a study of
2,311 diverse cancers (12). Among the 33 focal amplifications in GI cancers, 42%
overlapped with peak regions in other cancers (Fig. S10), including 11 regions containing
the known oncogenes MCL1, MYB, EGFR, FGFR1, MYC, CCND1, KRAS, MDM2,
ERBB2, and CCNE1 (marked with asterisks in Fig 3). Peak regions present in gut, but
absent from non-gut adenocarcinomas, encompassed genes encoding the tissue-specific
transcription factors GATA4 and GATA6 and the known or putative oncogenes CDK6,
FGFR2, MET, EPHB3, and EPHB6. Some of these genes are occasionally amplified in
other cancer types, but did not show statistical significance. HMGA2 amplifications on
chromosome 12 are notably absent in GI tumors, despite the presence of chromosome 12
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amplification at MDM2 in both GI and non-GI carcinomas. Similarly, amplification of the
G1/S cell cycle dependent-kinase CDK6 is restricted to GI tumors while CDK4
amplification is significant in all other tumors further suggesting that many cancer utilize
similar pathways with multiple inputs to reach the same output (Table S3).
Comparison of focal deletions—We identified 16, 8, and 21 peaks of significant
deletion in CRC, GC, and EA, respectively (Figs. 3B and S11 and Table S4). Six peaks were
shared across the three cancer types, all containing genes spanning large genomic loci
(including FHIT, WWOX, and MACROD2) (12, 42).
Seven deletion peaks were unique to CRC, including two peaks that encompass known
tumor suppressors (APC and PTEN), and five that do not. Among the latter, a previously
unidentified peak at 10q25 contains the apoptosis effector caspase gene CASP7, suggesting
a mechanism to evade apoptosis (Table S4A).
Eleven deletion peaks were unique to EA while none were unique to GC (Fig. 3B). Among
the EA peaks, two contain known esophageal tumor suppressors (CDKN2A and ATM;
Table S4B and Fig. S7D). One peak contains RUNX1, which we consider further below.
Two peaks were seen in both esophageal and gastric tumors, including one large gene
(PTPRD) and one region (6p25.3) with no known tumor suppressor.
Among the 30 deletion peaks in the composite tumor set (Table 2), 15 were also significant
in the non-GI adenocarcinoma study (Fig. S10). The common sites included nine peaks
encompassing large genes, four peaks containing known deleted tumor suppressors (APC,
CDKN2A, ATM, and PTEN), and two peaks without either. One of the latter peaks contains
the effector caspase gene CASP3, suggesting that deletion of an effector caspase, CASP3 or
CASP7, may mark GI adenocarcinomas more generally and not CRC alone. Focal loss of
RB1 and TP53 were identified in non-GI but not in digestive tract adenocarcinomas,
although 17p deletion, containing TP53, was significant in CRC and EAC. The 15 deletion
peaks restricted to GI adenocarcinomas include 13 that lack known tumor suppressors
(Table S5). The other two contain the known tumor suppressors SMAD4 and RUNX1.
Functional significance of RUNX1 deletions in esophageal adenocarcinoma
We observed highly focal RUNX1 deletions at 21q22.12 in 15% of EAs, also noted in a
recent report (Fig. 5A) (36). RUNX1 behaves as a tumor suppressor in leukemia, where
translocations and mutations disrupt gene function (43). We therefore evaluated a possible
tumor suppressor function for RUNX1 in EA by reintroducing it into the EA cell line OE33,
which carries a focal RUNX1 deletion (Fig. 5A). We observed a 69% reduction in
anchorage-independent growth relative to GFP-infected cells (Fig. 5B-C). As we did not
possess an EA cell line without deletion at the RUNX1 locus, we ectopically expressed
RUNX1 in A549 lung cancer cells, which have no focal RUNX1 deletion, to evaluate for
generalized cellular toxicity due to overexpression of this gene. In contrast to OE33 cells,
RUNX1 expression did not significantly affect A549 colony formation (Fig. 5B-C). These
results are consistent with a potential role for RUNX1 as a tumor suppressor in EA.
Discussion
These data provide the most comprehensive, high-resolution analysis to date of SCNA
patterns across the three most common forms of gut adenocarcinoma. Our cohort size
enhanced the ability to detect significant SCNAs, and we identified several focused areas of
recurrent genomic alteration pointing toward genes that may contribute to cancer. Notably,
the genomes of EA and GC cancers contain alterations selected for their contributions to the
process of both intestinal metaplasia and malignant transformation to adenocarcinoma.
Dulak et al. Page 7
Cancer Res. Author manuscript; available in PMC 2013 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
We observed more focal amplifications in upper GI adenocarcinomas compared to CRC.
Unlike CRC, EA and GC emerge in a setting of bile and acid injury, which may generate
DNA strand breaks and contribute to the high rates of SCNA (44). Alternatively, distinct
DNA repair pathways or selection for differing stimuli may account for these differences. It
is unclear why the enhanced rates of focal amplifications in EA/GC were not matched by a
similarly increased rate of focal deletions nor why the rates of deletion in GC fell below
those in EA or CRC. Although the loci of the most significant amplifications peaks fell at
known or plausible oncogenes, many focal deletions peaks lie in potential fragile sites. Thus,
the mechanisms and selection pressures underlying deletions may differ from those
responsible for amplification.
The GATA6 and GATA4 transcription factor genes lie in the second and sixth most
significant amplification peaks across the full dataset, respectively. The developmental role
of these transcription factors and selective amplification in GI cancers suggests that they
may add to the growing number of lineage-survival transcription factor oncogenes (45). A
parallel phenomenon is amplification of SOX2 in squamous esophageal and lung
carcinomas (46), an event absent in EA.
A key clinical observation emerging from these data is that focally amplified RTKs were
observed most prominently in EA and GC, suggesting that genomic amplifications will be
more important biomarkers in upper gastrointestinal cancers than in CRC. Recent clinical
trials reveal benefit when the HER2-directed antibody trastuzumab is combined with
chemotherapy in treating ERBB2-amplified or – overexpressing GC/EA (11). The presence
of ERBB2 amplifications in 6% of CRCs suggests that ERBB2-directed therapy may benefit
select CRC patients (47). Additionally, based on evidence that KRAS mutation negatively
predicts cetuximab response, highly prevalent KRAS amplification in upper GI tumors may
similarly impact clinical decisions. When KRAS is evaluated as a biomarker in upper GI
cancers, it will be important to examine both SCNAs and point mutations. Our data also
point to other genomic amplifications of clinical relevance. CDK6 (48) and VEGFA focal
amplifications may serve as a marker of response to targeted inhibitors. More broadly, these
data point to the inclusion of gene amplifications to guide therapy in upper gastrointestinal
adenocarcinomas.
While these data suggest that many patients with EA or GC may benefit from treatment
targeting an amplified RTK, it is unlikely that therapies directed against these targets alone
will lead to durable responses. The progression-free survival provided by single-agent
therapy with trastuzumab in GC/EA has been modest (11). The presence of complex SCNA
profiles in these tumors suggest there could be co-occurring alterations that confer primary
resistance (49) or enhanced genomic instability that speeds acquired resistance. In our
cohort, the rates of co-occurrence between RTK-associated and other events did not
significantly deviate from what would be expected for statistically independent events.
However, co-occurrences were detected, and the rates with which individual pairs of events
co-occur are likely to inform combinational treatment strategies. While evaluation of RTK-
targeted agents is needed, the genomic complexity and variability of these cancers suggests
that combination inhibitor strategies will ultimately be essential.
Beyond these immediately clinically relevant targets, these data provide enhanced insight
into specific genes responsible for different subtypes of gastrointestinal adenocarcinoma.
Despite a shared intestinal origin, upper gastrointestinal cancers exhibit many distinct events
from those seen in CRC, such as alteration of cell cycle regulators (CCND1, CCNE1,
CDK6, CDKN2A). Moreover, as evidenced by the selective deletion of RUNX1 in EA,
clear genomic differences exist between EA and GC. While our analysis has helped identify
loci of recurrent alteration and potential targets of these events, many recurrent regions of
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SCNA do not contain known oncogenes or tumor suppressors. One challenge moving
forward will be to determine which of these regions harbor additional genes or non-coding
elements that contribute toward intestinal metaplasia or transformation to cancer. High-
resolution genome analyses of large sample numbers, as presented here, can guide future
studies and inform the development of strategies to reverse the effects of the somatic genetic
events that drive these cancers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Patterns of chromosomal instability differ across adenocarcinomas of the
gastrointestinal tract
a) Amplifications (red) and deletions (blue) are displayed for 486 gut adenocarcinomas (x-
axis) across the genome (y-axis). Quantitation of b) arm-level and c) focal SCNAs. Solid
bars represent median numbers of events per sample. Error bars represent S.E.M. d)
Quantitation of inferred multi-copy SCNAs (high-level amplifications with inferred copy >4
and presumable homozygous deletions, inferred copy-number <1.3). ***, P < 0.0005; **, P
< 0.005; *, P < 0.05; n.s., not significant.
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Figure 2. Identification of significant focal SCNAs in a cohort of esophageal, gastric, and
colorectal adenocarcinomas
GISTIC q-values (x-axis) for deletions (left, blue) and amplifications (right, red) are plotted
across the genome (y-axis). The 10 most significant peaks are labeled with known or
putative gene targets. Values in parentheses represent the number of genes in the peak
region. Asterisks indicate genes immediately adjacent to the peak.
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Figure 3. Venn diagram of focal events common across gut adenocarcinomas
Significantly amplified (a) or deleted (b) peaks (or gene if likely candidate available) as
determined by GISTIC analysis of focal alterations in each adenocarcinoma subtype. The
color code denotes peaks that are unique to a given tumor type or shared between two or
three of the adenocarcinoma subtypes. Bolded genes represent genes significantly altered
and common across esophageal, gastric, and colorectal tumors. Asterisks represent
significant SCNAs in a dataset containing 3,131 cancers not including CRC, EA or GC (12).
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Figure 4. Amplified therapeutic determinants in gut adenocarcinomas
The presence of focal amplifications (inferred copy-number > 2.3) is shown in red for
recurrently amplified receptor tyrosine kinase genes across all tumor specimens (vertical
bars).
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Figure 5. RUNX1 re-expression can inhibit anchorage-independent growth in an esophageal
adenocarcinoma cell model
a) Focal deletion of locus 21q22.12 containing RUNX1 in esophageal adenocarcinomas,
OE33 (EA), and A549 (non-small cell lung cancer) cell lines. b) OE33 and A549 cell lines
were stably transduced with retrovirus containing RUNX1. Immunoblotting confirmed
positive expression of RUNX1. c) Soft-agar colony formation for OE33 and A549 cells with
ectopic GFP or RUNX1 expression. Representative images of colony formation at 6.3X
magnification. Quantitation of three independent experiments; error bars represent S.E.M.
**, P < 0.005; n.s., not significant.
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